Dtsch Med Wochenschr 2006; 131(46 spezial): H24-H27
DOI: 10.1055/s-2006-955058
Fortbildungsbeiträge | Continuing Medical Education
Hypertensiologie, Endokrinologie
© Georg Thieme Verlag KG Stuttgart · New York

Normokaliämischer primärer Hyperaldosteronismus

Normokalemic primary hyperaldosteronismO. Vonend1 , L. C. Rump1
  • 1Medizinische Klinik I (Schwerpunkte Nephrologie, Hypertonie und Schlafmedizin), Klinikum der Ruhr-Universität Bochum, Marienhospital Herne
Further Information

Publication History

Publication Date:
09 November 2006 (online)

Literatur

  • 1 Buchner N, Vonend O, Rump L C. Pathophysiologie der Hypertonie. Was gibt es Neues?.  Herz. 2006;  31 294-302
  • 2 Calhoun D A, Nishizaka M K, Zaman M A, Thakkar R B, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension.  Hypertension. 2002;  40 892-896
  • 3 Conn J W, Cohen E L, Rovner D R, Nesbit R M. Normokalemic primary aldosteronism. A detectable cause of curable „essential” hypertension.  Jama. 1965;  193 200-206
  • 4 Espiner E A, Ross D G, Yandle T G, Richards A M, Hunt P J. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling.  J Clin Endocrinol Metab. 2003;  88 3637-3644
  • 5 Gordon R D. Primary aldosteronism - actual epidemics or false alarm?.  Arq Bras Endocrinol Metabol. 2004;  48 666-673
  • 6 Griffing G T, Melby J. The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism.  Clin Exp Hypertens A. 1983;  5 779-801
  • 7 Hagemeister J, Schneider C A, Barabas S, Schadt R, Wassmer G. et al . Hypertension guidelines and their limitations - the impact of physicians’ compliance as evaluated by guideline awareness.  J Hypertens. 2001;  19 2079-2086
  • 8 Harper R, Ferrett C G, McKnight J A, McIlrath E M, Russell C F. et al . Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas.  QJM. 1999;  92 643-650
  • 9 Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C. et al . Efficacy and tolerance of spironolactone in essential hypertension.  Am J Cardiol. 1987;  60 820-825
  • 10 Kaperonis N, Bakris G. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans.  Curr Opin Nephrol Hypertens. 2003;  12 79-84
  • 11 Kaplan N M. The current epidemic of primary aldosteronism: causes and consequences.  J Hypertens. 2004;  22 863-869
  • 12 Luft F C. Mendelian forms of human hypertension and mechanisms of disease.  Clin Med Res. 2003;  1 291-300
  • 13 Meria P, Kempf B F, Hermieu J F, Plouin P F, Duclos J M. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases.  J Urol. 2003;  169 32-35
  • 14 Milliez P, Girerd X, Plouin P F, Blacher J, Safar M E. et al . Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.  J Am Coll Cardiol. 2005;  45 1243-1248
  • 15 Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F. et al . Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.  Hypertension. 2002;  40 897-902
  • 16 Nadler J L, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism.  J Clin Endocrinol Metab. 1985;  60 896-899
  • 17 Quinkler M, Reincke M. Moderne pharmakologische Aspekte der Therapie des Aldosteronismus.  Internist (Berl). 2006;  47 953-959
  • 18 Reincke M, Seiler L, Rump L C. Normokaliämischer primärer Hyperaldosteronismus.  Dtsch Arztebl. 2003;  100 A184-A190
  • 19 Rossi E, Regolisti G, Negro A, Sani C, Davoli S. et al . High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives.  Am J Hypertens. 2002;  15 896-902
  • 20 Seiler L, Rump L C, Schulte-Monting J, Slawik M, Borm K. et al . Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.  Eur J Endocrinol. 2004;  150 329-337
  • 21 Vonend O, Altenhenne C, Büchner N J, Dekomien G, Maser-Gluth C. et al . A German family with glucocorticoid remediable aldosteronism.  Nephrol Dial Transplant 2006,. , revision submitted
  • 22 White P C. Aldosterone: direct effects on and production by the heart.  J Clin Endocrinol Metab. 2003;  88 2376-2383
  • 23 Wolf-Maier K, Cooper R S, Banegas J R, Giampaoli S, Hense H W. et al . Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.  J Am Med Assoc. 2003;  289 2363-2369
  • 24 Young W F. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment.  Endocrinology. 2003;  144 2208-2213
  • 25 Young W F, Klee G G. Primary aldosteronism: Diagnostic evaluation.  Endocrinol Metab Clin North Am. 1988;  17 367-395

Prof. Dr. Lars Christian Rump

Medizinische Klinik I, Marienhospital Herne

Hölkeskampring 40

44625 Herne

Phone: 02323/4991671

Fax: 02323/499302

Email: christian.rump@ruhr-uni-bochum.de

    >